Search - tctmd.com

Displaying 1 - 20 of 315

Sort: Relevancy | Date

Presentation TCT 2016

Management of Residual Leaks After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw

November 01, 2016

Presentation TCT 2016

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Presenter: Aaron V. Kaplan, Rachel Neubrander, Tamara Syrek Jensen

November 01, 2016

Presentation TCT 2016

Follow-up Evaluation After LAA Closure

Presenter: David R. Holmes Jr., Jacqueline Saw, Bushra S Rana

November 01, 2016

Presentation TCT 2016

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Presenter: Aaron V. Kaplan, Rachel Neubrander, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Presenter: Aaron V. Kaplan, Rachel Neubrander, Katherine Wallon

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Lariat

Presenter: Krzysztof Bartus, Randall J. Lee

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Lifetech LAA Occluder

Presenter: Krzysztof Bartus, Yat-Yin Lam

November 01, 2016

Presentation TCT 2016

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Cardia LAA Occluder

Presenter: Krzysztof Bartus, Josep Rodés-Cabau

November 01, 2016

Presentation TCT 2016

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Occlutech LAA Occluder

Presenter: Krzysztof Bartus, Eustaquio Maria Onorato

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the WaveCrest LAA Occluder

Presenter: Krzysztof Bartus, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

Case Presentation: LAA Intervention in the TAVR Patient

Presenter: Bagrat Alekyan, Grzegorz L. Kaluza, Alexey Protopopov

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the ACP/Amulet LAA Occluder

Presenter: Krzysztof Bartus, Jai-Wun Park

November 01, 2016

Presentation TCT 2016

Special Tips and Tricks for LAA Closure Using the Watchman LAA Occluder

Presenter: Krzysztof Bartus, Saibal Kar

November 01, 2016

Presentation TCT 2016

General Principles of LAA Closure

Presenter: Krzysztof Bartus, Apostolos Tzikas

November 01, 2016

Presentation TCT 2016

The Potential for 3D Printing and Imaging for LAA Closure

Presenter: Samir R. Kapadia, Apostolos Tzikas, James K. Min

November 01, 2016

Advertisement

Management of Residual Leaks After LAA Closure

Assessment and Implications of Residual Leaks After Percutaneous and Surgical LAA Closure

Reimbursement Challenges For LAAC: Balancing The Clinical Need Vs. Robust Data Vs. Societal Economic Considerations

Follow-up Evaluation After LAA Closure

Pivotal Trial Design Considerations: Noninferiority vs Superiority, Device, Control Arm Anticoagulation Durations, NOAC Considerations and More Industry and Clinician Perspectives

Trial Designs For LAA Closure: Potential Regulatory Pathways and Unanswered Questions What FDA Would Like to See

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Special Tips and Tricks for LAA Closure Using the Lariat

Special Tips and Tricks for LAA Closure Using the Lifetech LAA Occluder

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Special Tips and Tricks for LAA Closure Using the Cardia LAA Occluder

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Special Tips and Tricks for LAA Closure Using the Occlutech LAA Occluder

Special Tips and Tricks for LAA Closure Using the WaveCrest LAA Occluder

Case Presentation: LAA Intervention in the TAVR Patient

Special Tips and Tricks for LAA Closure Using the ACP/Amulet LAA Occluder

Special Tips and Tricks for LAA Closure Using the Watchman LAA Occluder

General Principles of LAA Closure

The Potential for 3D Printing and Imaging for LAA Closure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content